Dyax (NASDAQ: DYAX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Dyax to related businesses based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, analyst recommendations and risk.
This table compares Dyax and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of current ratings and target prices for Dyax and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.40%. Given Dyax’s competitors higher probable upside, analysts plainly believe Dyax has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Dyax and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dyax Competitors||$284.49 million||$34.10 million||78.03|
Dyax’s competitors have higher revenue and earnings than Dyax. Dyax is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Dyax competitors beat Dyax on 5 of the 8 factors compared.
Dyax Company Profile
Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Receive News & Ratings for Dyax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyax and related companies with MarketBeat.com's FREE daily email newsletter.